These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 480011)

  • 21. Circadian patterns of plasma cortisol, 17-hydroxyprogesterone, and testosterone in congenital adrenal hyperplasia.
    Frisch H; Parth K; Schober E; Swoboda W
    Arch Dis Child; 1981 Mar; 56(3):208-13. PubMed ID: 7212759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationships between serum concentrations of 17OH-progesterone and other serum and urinary steroids in patients with congenital adrenal hyperplasia.
    Hughes IA; Winter JS
    J Clin Endocrinol Metab; 1978 Jan; 46(1):98-104. PubMed ID: 752027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia.
    Sarafoglou K; Zimmerman CL; Gonzalez-Bolanos MT; Willis BA; Brundage R
    J Investig Med; 2015 Jan; 63(1):35-41. PubMed ID: 25386671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia.
    Spritzer P; Billaud L; Thalabard JC; Birman P; Mowszowicz I; Raux-Demay MC; Clair F; Kuttenn F; Mauvais-Jarvis P
    J Clin Endocrinol Metab; 1990 Mar; 70(3):642-6. PubMed ID: 2137832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgens concentrations and second-to fourth-digit ratio (2D:4D) in girls with congenital adrenal hyperplasia (21-hydroxylase deficiency).
    Oswiecimska JM; Ksiazek A; Sygulla K; Pys-Spychala M; Roczniak GR; Roczniak W; Stojewska M; Ziora K
    Neuro Endocrinol Lett; 2012; 33(8):787-91. PubMed ID: 23391972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma insulin-like growth factor I levels during treatment of congenital adrenal hyperplasia.
    Cavallo A; Furlanetto RW; Meyer WJ
    Horm Res; 1990; 34(1):23-6. PubMed ID: 2074088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Scalp hair 17-hydroxyprogesterone and androstenedione as a long-term therapy monitoring tool in congenital adrenal hyperplasia.
    Noppe G; de Rijke YB; Koper JW; van Rossum EF; van den Akker EL
    Clin Endocrinol (Oxf); 2016 Oct; 85(4):522-7. PubMed ID: 27061431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of long acting glucocorticoids on menstrual abnormalities in patients with virilizing congenital adrenal hyperplasia.
    Richards GE; Grumbach MM; Kaplan SL; Conte FA
    J Clin Endocrinol Metab; 1978 Dec; 47(6):1208-15. PubMed ID: 233693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Congenital adrenal hyperplasia: case report in dizygotic twins.
    Tze WJ; Fisher JN; Crigler JF
    Pediatrics; 1972 Jul; 50(1):137-9. PubMed ID: 5038089
    [No Abstract]   [Full Text] [Related]  

  • 30. Plasma adrenocorticotrophic hormone in congenital adrenal hyperplasia. Importance in long-term management.
    LaFranchi S
    Am J Dis Child; 1980 Nov; 134(11):1068-72. PubMed ID: 6254355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum 17-alpha-hydroxyprogesterone, progesterone, estradiol, and testosterone in the diagnosis and management of congenital adrenal hyperplasia.
    Lippe BM; LaFranchi SH; Lavin N; Parlow A; Coyotupa J; Kaplan SA
    J Pediatr; 1974 Dec; 85(6):782-7. PubMed ID: 4371221
    [No Abstract]   [Full Text] [Related]  

  • 32. Gonadotropin output in congenital adrenal hyperplasia before and after adrenal suppression.
    Klingensmith GJ; Wentz AC; Meyer WJ; Migeon CJ
    J Clin Endocrinol Metab; 1976 Oct; 43(4):933-6. PubMed ID: 185235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [17-hydroxyprogesterone, testosterone and androstenedione in treated congenital adrenogenital syndrome].
    von Schnakenburg K; Bidingmaier F; Knorr D
    Monatsschr Kinderheilkd (1902); 1977 May; 125(5):579-80. PubMed ID: 876244
    [No Abstract]   [Full Text] [Related]  

  • 34. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty.
    Bonfig W; Bechtold S; Schmidt H; Knorr D; Schwarz HP
    J Clin Endocrinol Metab; 2007 May; 92(5):1635-9. PubMed ID: 17299071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Determination of serum steroids in monitoring therapy of congenital adrenal hyperplasia].
    Xiao HW; Ma HM; Su Z; Du ML; Li YH; Chen HS; Chen QL
    Zhonghua Er Ke Za Zhi; 2012 Apr; 50(4):301-7. PubMed ID: 22801236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Precocious pubarche: distinguishing late-onset congenital adrenal hyperplasia from premature adrenarche.
    Armengaud JB; Charkaluk ML; Trivin C; Tardy V; Bréart G; Brauner R; Chalumeau M
    J Clin Endocrinol Metab; 2009 Aug; 94(8):2835-40. PubMed ID: 19454583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth and skeletal maturation in congenital adrenal hyperplasia. Review of 20 cases.
    Bailey CC; Komrower GM
    Arch Dis Child; 1974 Jan; 49(1):4-7. PubMed ID: 4361889
    [No Abstract]   [Full Text] [Related]  

  • 38. Congenital adrenal hyperplasia.
    Newns GH
    Arch Dis Child; 1974 Jan; 49(1):1-3. PubMed ID: 4361888
    [No Abstract]   [Full Text] [Related]  

  • 39. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Völkl TM; Simm D; Beier C; Dörr HG
    Pediatrics; 2006 Jan; 117(1):e98-105. PubMed ID: 16396852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of hormonal control on LH pulsatility and secretion in women with classical congenital adrenal hyperplasia.
    Bachelot A; Chakhtoura Z; Plu-Bureau G; Coudert M; Coussieu C; Badachi Y; Dulon J; Charbit B; Touraine P;
    Eur J Endocrinol; 2012 Oct; 167(4):499-505. PubMed ID: 22893695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.